Removal of bowel aerobic gram-negative bacteria is more effective than immunosuppression with cyclophosphamide and steroids to decrease natural alpha-galactosyl IgG antibodies.
Natural alpha-Galactosyl (Gal) antibodies play an important role in the rejection of pig xenografts by humans and Old World monkeys. In this study we investigate the efficacy of two different strategies to reduce the serum level of natural anti-Gal antibodies. On the one hand, removal of aerobic gram-negative bacteria from the intestinal flora, because anti-Gal antibodies appear to be produced as a result of the continuous sensitization by these microorganisms. On the other hand, we studied the effect on these antibodies of an immunosuppressive regimen of cyclophosphamide and steroids. Ten baboons were treated for three months with norfloxacin (Nor Group; n=6) or cyclophosphamide and steroids (CyP Group; n=4). A further four baboons did not receive any treatment (Control Group). Aerobic gram-negative bacteria became negative in stools of the Nor Group after two weeks of treatment, and remained undetectable until week 7. Thereafter, a gradual increase on the fecal concentration of aerobic gram-negative bacteria was observed despite the norfloxacin treatment. The mean anti-Gal IgG in the Nor Group gradually declined from week 4 to 9 to a mean of 62.7 +/- 18% of the baseline level, and during this period were significantly lower than in the CyP (P<0.02) and the Control (P<0.05) groups. No differences were observed between the three groups during the 16 weeks of follow-up in serum levels of anti-Gal IgM, hemolytic anti-pig antibodies, total IgG, IgM and IgA. In conclusion, removal of normal aerobic gram-negative bacteria from the intestinal flora is more effective than immunosuppression with CyP and steroids in reducing the level of natural anti-Gal antibodies, although there is no discernible effect on IgM antibodies.
Mañez
R
R
Juan Canalejo Medical Center and University of La Coruña Health Institute, Spain.
Blanco
F J
FJ
Díaz
I
I
Centeno
A
A
Lopez-Pelaez
E
E
Hermida
M
M
Davies
H F
HF
Katopodis
A
A
D000818:Animals; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000276:immunology; D004187:Disaccharides / Q000276:immunology*; D006084:Graft Rejection / Q000276:immunology; D006088:Gram-Negative Aerobic Bacteria / Q000276:immunology*; D000882:Haplorhini; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000276:immunology; D013256:Steroids / Q000008:administration & dosage / Q000276:immunology; D013552:Swine; D014183:Transplantation, Heterologous / Q000276:immunology*
D004187:Disaccharides; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D013256:Steroids; D003520:Cyclophosphamide